⚕ GalenOps CRO console
← SITE003 (CAN)

SITE003-0403

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE003 (CAN) (Dr. Okafor) · consented 2023-07-03
Adverse events
10
Serious AEs
1
Open data queries
0
Luna dropout signal
–

Adverse events

mild assessed 2026-08-18

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-08-16 (study day 24); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Aspartate aminotransferase increased — outcome: RECOVERED/RESOLVED; onset 2023-09-19 (study day 58); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-10-10 (study day 79); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-01-28 (study day 189); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-02-29 (study day 221); relationship: N

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-03-08 (study day 229); relationship: N

moderate assessed 2026-08-18

Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2024-03-18 (study day 239); relationship: N

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-04-22 (study day 274); relationship: not assessed

severe serious assessed 2026-08-18

Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-06-12 (study day 325); relationship: not assessed; serious criteria: hospitalization

mild assessed 2026-08-18

Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2024-06-21 (study day 334); relationship: N

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.